You are here

RGT-075

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

Drugs.com

Sun, 03/10/24 - 08:28 pm

Regor Therapeutics

clinical trials